Table 2

Susceptibilities of Gram-positive aerobic bacteria to eravacycline and comparatorsa

OrganismMIC50/90 (μg/ml), MIC range (μg/ml), and no. of isolates
ERVTETTGCDAPLZDVANLEVMACRO
Enterococcus faecalis0.06/0.1332/>320.13/0.252/42/22/>64>8/>32>8/>8
≤0.016–0.130.13–>32≤0.016–0.50.13–8≤0.5–320.5–>640.25–>32≤0.13–>8
1949819419419415019459
Enterococcus faecalis VSE0.06/0.1332/>320.13/0.252/42/21/22/>32>4/>8
≤0.016–0.130.13–>32≤0.016–0.50.13–8≤0.5–320.5–40.25–>32≤0.13–>8
121701211211219212138
Enterococcus faecalis VRE0.06/0.1332/>320.13/0.252/42/2>64/>64>32/>32>8/>8
≤0.016–0.131–>320.03–0.250.13–81–8>16–>640.25–>322–>8
7328737373587321
Enterococcus faecalis FQ-R0.06/0.1332/>320.13/0.252/42/2>64/>64>32/>32>8/>8
≤0.016–0.130.13–>32≤0.016–0.5≤0.5–81–321–>64>4–>32≤0.13–32
111481111111118711134
Enterococcus faecium0.06/0.06≤2/>320.06/0.134/82/42/>64>32/>32>8/>8
≤0.016–0.50.25–>32≤0.016–0.51–16≤0.5–32≤0.5–>640.25–>320.25–>8
1535915315315310815356
Enterococcus faecium VSE0.06/0.131/>320.06/0.134/82/21/1>8/>32>8/>8
0.03–0.50.25–>320.03–0.251–81–4≤0.5–40.25–>320.25–>8
8433848484588433
Enterococcus faecium VRE0.06/0.0632/>320.06/0.134/82/4>64/>64>32/>32>8/>8
≤0.016–0.250.25–>320.03–0.51–16≤0.5–32>16–>641–>328–>8
6926696969496924
Enterococcus faecium FQ-R0.06/0.062/>320.06/0.124/82/432/>64>32/>32>8/>8
≤0.016–0.50.25–>32≤0.016–0.51–16≤0.5–32≤0.5–>64>4–>32>4–>8
127481271271278812745
Enterococcus faecium DAP-NS0.06/0.06ND0.06/0.138/164/4>64/>64>32/>32ND
≤0.016–0.5ND0.03–0.258–161–320.5–>642–>32ND
44ND4444444444ND
Enterococcus spp.0.03/0.060.5/320.13/0.130.5/22/2ND1/>80.5/>8
≤0.016–0.13≤0.06–>32≤0.016–0.250.25–41–2ND≤0.13–>8≤0.13–>8
2929292929ND2929
Staphylococcus aureus0.06/0.250.25/320.13/0.251/12/41/11/32>8/>32
≤0.016–40.06–>64≤0.016–160.063–41–640.5–80.06–>640.13–>64
408245408407407258399237
MRSA0.06/0.130.25/320.13/0.251/12/41/18/>32>8/>32
0.016–40.063–>64≤0.016–10.063–41–640.5–80.06–>640.13–>64
284177284283283202275169
MRSA PVL+0.03/0.030.25/0.250.13/0.130.5/11/21/10.25/>2>4/>4
≤0.016–0.030.13–0.250.06–0.130.5–11–21–10.25–>21–>4
3030303030303030
Staphylococcus aureus MACRO-Rb0.06/0.250.25/320.13/0.250.5/12/41/18/32>8/>32
≤0.016–40.06–>64≤0.016–160.13–41–640.5–80.06–>64>4–>64
13213213213113170132132
Staphylococcus aureus FQ-R0.06/0.130.25/320.12/0.251/12/41/1>8/>32>8/>32
≤0.016–20.06–>64≤0.016–160.125–21–640.5–8>2–>640.25–>64
178109178178178126174105
Staphylococcus aureus MACRO-R, FQ-R0.06/0.250.25/>320.13/0.250.5/12/41/2>8/32>8/>32
≤0.016–20.06–>64≤0.016–160.13–21–640.5–8>2–>64>4–>64
8383838383458383
MSSA0.13/0.250.5/10.13/0.251/14/41/10.25/11/>8
0.03–0.250.25–320.06–0.250.25–12–40.5–20.13–>320.25–>8
124681241241245612468
Coagulase-negative staphylococci0.06/0.50.25/320.25/11/12/21/20.5/>320.5/>8
≤0.016–2≤0.06–>320.03–20.25–2≤0.5–40.5–20.13–>32≤0.13–>8
1655916516516511116559
Coagulase-negative staphylococci, methicillin sensitive0.06/0.50.25/320.25/11/12/21/20.25/>80.25/>8
≤0.016–1≤0.06–>320.03–20.25–2≤0.5–40.5–20.13–>32≤0.13–>8
8937898989548937
Coagulase-negative staphylococci, methicillin resistant0.06/0.50.25/>320.13/0.51/11/21/28/>32>4/>8
0.03–20.25–>320.06–10.25–2≤0.5–20.5–20.13–>320.25–>8
7622767676577622
Streptococcus pneumoniae0.016/0.0160.25/>80.016/0.03≤0.03/0.50.5/10.25/0.51/12/>2
≤0.008–0.03≤0.03–>8≤0.008–0.06≤0.03–2≤0.13–20.13–0.5≤0.03–>8≤0.03–>2
18210018218218282182100
Streptococcus pneumoniae penicillin resistantc0.016/0.016>8/>80.016/0.03≤0.03/0.50.5/10.25/0.251/1>2/>2
≤0.008–0.030.13–>8≤0.008–0.03≤0.03–0.50.25–10.13–0.50.5–>8≤0.03–>2
6033606060276033
Streptococcus pneumoniae MACRO-Rd≤0.008/0.016>8/>80.016/0.03≤0.03/≤0.030.5/0.5ND1/1>2/>2
≤0.008–0.016≤0.03–>8≤0.008–0.03≤0.03–0.130.25–1ND0.5–>82–>2
5353535353ND5353
Streptococcus pneumoniae penicillin resistant, MACRO-R≤0.008/0.016>8/<80.016/0.03≤0.03/≤0.030.5/0.5ND1/1>2/>2
≤0.008–0.0160.13–>8≤0.008–0.03≤0.03–≤0.030.25–0.5ND0.5–>82–>2
2929292929ND2929
Streptococcus pneumoniae TET-R≤0.008/0.016>8/>80.016/0.03≤0.03/≤0.030.5/0.5ND1/1>2/>2
≤0.008–0.016>8–>8≤0.008–0.03≤0.03–0.060.25–0.5ND0.5–>22–>2
3434343434ND3434
Streptococcus pyogenes0.03/0.030.25/0.250.03/0.060.13/0.131/2ND0.5/10.06/0.06
0.015–0.130.13–>8≤0.016–0.13≤0.03–0.250.5–2ND0.25–2≤0.03–0.13
7420747474ND7420
Streptococcus agalactiae0.03/0.06>8/>80.03/0.060.06/0.51/20.5/0.50.5/10.06/>4
0.016–0.060.25–>80.016–0.13≤0.03–10.5–20.25–0.50.5–2≤0.03–>4
123791231231234812379
Streptococcus anginosus0.016/0.0310.5/>160.016/0.060.25/0.51/20.5/10.5/10.03/>0.5
≤0.008–0.13≤0.06–>16≤0.008–0.25≤0.03–0.5≤0.25–2≤0.008–1≤0.25–2≤0.016–>2
4747472547462525
Streptococcus intermedius0.016/0.060.25/>40.03/0.130.5/11/10.5/0.51/20.06/>0.5
≤0.008–0.06≤0.06–>4≤0.008–0.25≤0.03–>1≤0.25–1≤0.06–0.5≤0.25–>4≤0.016–>0.5
3131313131313031
Streptococcus mitis0.016/0.060.5/>40.03/0.130.5/11/10.5/0.51/2>0.5/>0.5
≤0.008–0.060.13–>8≤0.008–0.250.06–>10.5–1≤0.06–10.5–>4≤0.016–>2
3232323232313232
Streptococcus spp.0.016/0.131/>80.03/0.130.13/10.5/10.5/11/20.06/>2
≤0.008–0.25≤0.06–>8≤0.008–0.25≤0.03–1≤0.25–2≤0.06–1≤0.25–2≤0.016–>2
6262626262216262
  • a MACRO, macrolide (erythromycin, azithromycin, or clarithromycin); ND, not determined; ERV, eravacycline; TET, tetracycline; TGC, tigecycline; DAP, daptomycin; LZD, linezolid; VAN, vancomycin; LEV, levofloxacin; DAP-NS, daptomycin nonsusceptible; PVL+, Panton-Valentine leukocidin positive.

  • b Macrolide-resistant staphylococci were defined as having an erythromycin/azithromycin/clarithromycin MIC of ≥8 μg/ml.

  • c Penicillin-resistant streptococcal isolates were defined as having an MIC of ≥2 μg/ml for the oral penicillin breakpoint.

  • d Macrolide-resistant streptococcal isolates were defined as having an erythromycin/clarithromycin MIC of ≥1 μg/ml and an azithromycin MIC of ≥2 μg/ml.